Omega-backed start­up sells it­self qui­et­ly; Ab­b­Vie breaks out more Rin­voq da­ta; Re­vance gets FDA date for Botox ri­val

6 years ago
News Briefing

Ian Read adds a new post to his grow­ing ros­ter of post-Pfiz­er po­si­tions — and this one pays well

6 years ago
People
R&D

Roche/PTC edge clos­er to dis­rupt­ing mar­ket for SMA ri­vals Bio­gen and No­var­tis with more pos­i­tive da­ta

6 years ago
R&D

Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to ...

6 years ago
Financing

MD An­der­son emerges with strong ev­i­dence for nat­ur­al killer cell ther­a­py, and Take­da looks like a win­ner

6 years ago
R&D
Cell/Gene Tx

GSK’s vac­cines group — in­clud­ing R&D — faces heavy job cuts in lat­est re­struc­tur­ing

6 years ago
R&D

Dutch biotech scores €25M in small mol­e­cule bet to tack­le lyso­so­mal stor­age dis­or­ders

6 years ago
Financing
Startups

Jef­frey Blue­stone ex­its Park­er and switch­es fo­cus back to au­toim­mune dis­eases in cell ther­a­py 2.0 launch

6 years ago
R&D

Sanofi's R&D group spot­lights a big win for BT­Ki mul­ti­ple scle­ro­sis drug. But plen­ty of ques­tions re­main

6 years ago
R&D

Bio­gen shares rock­et up as My­lan's chal­lenge to Tec­fidera patents is slapped down

6 years ago
Pharma

Nestlé puts $200M more be­hind a treat­ment for peanut al­ler­gy

6 years ago
R&D

Drug pric­ing re­form ex­pect­ed to be biggest drag on bio­phar­ma in 2020; Beam up­sizes IPO of­fer­ing

6 years ago
News Briefing

Re­al-world da­ta get re­al dol­lars: GV, Bain help in­fuse $100M in­to Ve­r­ana Health as prag­mat­ic tri­al space heats up

6 years ago
Financing

Bill Gates pitch­es in on coro­n­avirus R&D and con­tain­ment ef­forts with $100M com­mit­ment

6 years ago
R&D
Coronavirus

EMA, FDA and WHO prep for new coro­n­avirus treat­ments, IVDs

6 years ago
R&D
FDA+

Ac­tive Biotech is back, with one last bid for the failed MS drug Te­va dis­card­ed

6 years ago
R&D

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

6 years ago
Deals
R&D

Glax­o­SmithK­line's lat­est makeover in­cludes auc­tion­ing off der­ma­tol­ogy, adding new tech and lay­offs. But how many?

6 years ago
R&D

Chi­na re­searchers tout in vit­ro da­ta for Gilead­'s an­tivi­ral against Wuhan virus — which they are try­ing to patent

6 years ago
China

Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it

6 years ago
Bioregnum
R&D

French can­cer-fo­cused mi­cro­bio­me play­er is flush with €18M Se­ries B in­jec­tion

6 years ago
Financing

Bay Area biotech CEO con­vict­ed of si­phon­ing off $2.6M to buy a home; Mer­ck wins Alzheimer's nod for in­som­nia pill

6 years ago
News Briefing

The Sanofi-part­nered start­up find­ing clin­i­cal tri­als for the 90%

6 years ago
Financing
Startups

HIV vac­cine re­mains Holy Grail as Sanofi/GSK reg­i­men dis­ap­points in large study

6 years ago
R&D
First page Previous page 870871872873874875876 Next page Last page
A service from the Financial Times